Rockwell Medical Receives Japanese Patent Issuance for Triferic(TM) GMP Formulation

Rockwell Medical, Inc. (NASDAQ: RMTI ), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Japan Patent Office that it